{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Mayer-Blackwell K"],"funding":["National Institute of Allergy and Infectious Diseases","NIAID NIH HHS","Center for AIDS Research, Duke University"],"pagination":["983313"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9597301"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["13"],"pubmed_abstract":["Many participants in HIV-1 vaccine trials, who have not previously been exposed to or vaccinated against HIV-1, display serum immunoglobulin antibodies that bind the gp41 region of HIV-1 envelope prior to vaccination. Previous studies have hypothesized that these pre-existing antibodies may be cross-reactive and may skew future vaccine responses. In 12 large studies conducted by the HIV Vaccine Trial Network (HVTN) (n=1470 individuals), we find wide variation among participants in the pre-vaccine levels of gp41-reactive antibodies as measured by the binding antibody multiplex assay (BAMA). In the absence of exposure to the gp41 immunogen, anti-gp41 IgG levels were temporally stable over 26-52 weeks in repeated measures of placebo recipients. The analysis revealed that the geometric mean of"],"journal":["Frontiers in immunology"],"pubmed_title":["Multi-trial analysis of HIV-1 envelope gp41-reactive antibodies among global recipients of candidate HIV-1 vaccines."],"pmcid":["PMC9597301"],"funding_grant_id":["U01 AI068614","U01 AI068635","UM1 AI068635","U01 AI068618","UM1 AI068614","P30 AI064518","UM1 AI068618","AI068618, AI068635, AI068614"],"pubmed_authors":["Potchen N","Heptinstall J","Minot SS","Sawant S","Mayer-Blackwell K","Kublin JG","Seaton K","Shen X","Tomaras GD","Johnson AM","Fiore-Gartland A"],"additional_accession":[]},"is_claimable":false,"name":"Multi-trial analysis of HIV-1 envelope gp41-reactive antibodies among global recipients of candidate HIV-1 vaccines.","description":"Many participants in HIV-1 vaccine trials, who have not previously been exposed to or vaccinated against HIV-1, display serum immunoglobulin antibodies that bind the gp41 region of HIV-1 envelope prior to vaccination. Previous studies have hypothesized that these pre-existing antibodies may be cross-reactive and may skew future vaccine responses. In 12 large studies conducted by the HIV Vaccine Trial Network (HVTN) (n=1470 individuals), we find wide variation among participants in the pre-vaccine levels of gp41-reactive antibodies as measured by the binding antibody multiplex assay (BAMA). In the absence of exposure to the gp41 immunogen, anti-gp41 IgG levels were temporally stable over 26-52 weeks in repeated measures of placebo recipients. The analysis revealed that the geometric mean of","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2026-06-01T02:25:32.8Z","creation":"2025-04-04T09:42:29.126Z"},"accession":"S-EPMC9597301","cross_references":{"pubmed":["36311720"],"doi":["10.3389/fimmu.2022.983313"]}}